US20120259308A1 - Goal-directed fluid therapy - Google Patents

Goal-directed fluid therapy Download PDF

Info

Publication number
US20120259308A1
US20120259308A1 US13/507,233 US201213507233A US2012259308A1 US 20120259308 A1 US20120259308 A1 US 20120259308A1 US 201213507233 A US201213507233 A US 201213507233A US 2012259308 A1 US2012259308 A1 US 2012259308A1
Authority
US
United States
Prior art keywords
patient
fluid
urine
hydration
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/507,233
Inventor
Mark Gelfand
Howard Levin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GCP IV LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US13/507,233 priority Critical patent/US20120259308A1/en
Publication of US20120259308A1 publication Critical patent/US20120259308A1/en
Assigned to GCP IV, LLC reassignment GCP IV, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PLC MEDICAL SYSTEMS, INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/20Measuring for diagnostic purposes; Identification of persons for measuring urological functions restricted to the evaluation of the urinary system
    • A61B5/201Assessing renal or kidney functions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/20Measuring for diagnostic purposes; Identification of persons for measuring urological functions restricted to the evaluation of the urinary system
    • A61B5/207Sensing devices adapted to collect urine
    • A61B5/208Sensing devices adapted to collect urine adapted to determine urine quantity, e.g. flow, volume
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/48Other medical applications
    • A61B5/4836Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/007Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests for contrast media
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A61M5/16886Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body for measuring fluid flow rate, i.e. flowmeters
    • A61M5/16895Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body for measuring fluid flow rate, i.e. flowmeters by monitoring weight change, e.g. of infusion container
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A61M5/172Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
    • A61M5/1723Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/36Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests with means for eliminating or preventing injection or infusion of air into body
    • A61M5/365Air detectors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01GWEIGHING
    • G01G17/00Apparatus for or methods of weighing material of special form or property
    • G01G17/04Apparatus for or methods of weighing material of special form or property for weighing fluids, e.g. gases, pastes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/18General characteristics of the apparatus with alarm
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/33Controlling, regulating or measuring
    • A61M2205/3331Pressure; Flow
    • A61M2205/3355Controlling downstream pump pressure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/33Controlling, regulating or measuring
    • A61M2205/3379Masses, volumes, levels of fluids in reservoirs, flow rates
    • A61M2205/3393Masses, volumes, levels of fluids in reservoirs, flow rates by weighing the reservoir

Definitions

  • This invention relates to a patient hydration system and method wherein the rate of hydration fluid delivered to the patient is automatically adjusted based on the urine output of the patient to maintain, as necessary, a zero, positive, or negative net fluid balance in the patient.
  • RCN radiocontrast nephropathy
  • RCN is the third most common cause of hospital-acquired renal failure. It occurs in over 5% of patients with any baseline renal insufficiency and in 50% of patients with preexisting chronic renal insufficiency and diabetes.
  • Radiocontrast media has a variety of physiologic effects believed to contribute to the development of RCN.
  • One of the main contributors is renal medullary ischemia, which results from a severe, radiocontrast-induced reduction in renal/intrarenal blood flow and oxygen delivery.
  • the medullary ischemia induces ischemia and/or death of the metabolically active areas of the medulla responsible for urine formation, called the renal tubules.
  • Medullary ischemia is attributed to the increase of oxygen demand by the kidney struggling to remove the radiocontrast media from blood plasma and excrete it from the body at the same time as the normal process of controlling the concentration of urine.
  • Oxygen consumption in the medulla of the kidney is directly related to the work of concentrating urine. Since the presence of radiocontrast media in the urine makes it much more difficult for the kidney to concentrate urine, the work of the medulla outstrips the available oxygen supply and leads to medullary ischemia.
  • a major limitation to the more widespread use of the already known therapeutic, or optimal, levels of I.V. hydration is the current inability to balance the amount of fluid going into the patient to the amount of fluid being removed or excreted from the patient. It is possible to have a nurse measure a patient's urine output frequently but this method is impractical as nurses are often responsible for the care of many patients.
  • the only accurate method of measuring urine output is to place a catheter into the patient's urinary bladder. Without a catheter, the patient must excrete the urine that may have been stored in the bladder for several hours. During this time, the amount of I.V. hydration can be significantly less than the amount of urine produced by the kidneys and stored in the bladder, leading to dehydration. Since patients do not normally have such a catheter during procedures using radiocontrast media, a valid measurement of urine output is not possible.
  • hydration therapy is given intravenously (I.V.) when someone is losing necessary fluids at a rate faster than they are retaining fluids.
  • I.V. intravenously
  • the patient receives the necessary fluids much faster than by drinking them.
  • dehydration can be heightened by hyperemesis (vomiting), therefore the I.V. method eliminates the need to take fluids orally.
  • An anesthetized or sedated patient may not be able to drink.
  • Hydration is used in clinical environments such as surgery, ICU, cathlab, oncology center and many others. At this time, hydration therapy is performed using inflatable pressure bags and/or I.V. pumps.
  • a number of I.V. pumps on the market are designed for rapid infusion of fluids (as opposed to slow I.V. drug delivery) for perioperative hydration during surgery, ICU use and even emergency use for fluid resuscitation.
  • An infusion pump is a device used in a health care facility to pump fluids into a patient in a controlled manner.
  • the device may use a piston pump, a roller pump, or a peristaltic pump and may be powered electrically or mechanically.
  • the device may also operate using a constant force to propel the fluid through a narrow tube, which determines the flow rate.
  • the device may include means to detect a fault condition, such as air in, or blockage of, the infusion line and to activate an alarm.
  • An example of a device for rapid infusion of fluids is the Infusion Dynamics (Plymouth Meeting, Pa.) Power Infuser.
  • the Power Infuser uses two alternating syringes as a pumping engine. Since it is only intended to deliver fluids (not medication), the Power Infuser has accuracy of 15%. It provides a convenient way to deliver colloid as well as crystalloid for hydration during the perioperative period among other possible clinical settings.
  • the Power Infuser provides anesthesiologists with the ability to infuse at rates similar to that seen with pressure bags, but with more exact volume control.
  • the maximum infusion rate is 6 L/hr. It has the flexibility of infusing fluid at 0.2, 1, 2, 4 and 6 L/hr. A bolus setting of 250 mL will deliver that volume in 2.5 min. In a large blood loss surgical case, the use of Power Infuser enables large volumes of colloid to be delivered to restore hemodynamics.
  • loop diuretics such as furosemide (frusemide) reduce sodium reabsorption and consequentially reduce oxygen consumption of the kidney. They also reduce concentration of contrast agents in the urine-collecting cavities of the kidney. They induce diuresis (e.g., patient produces large quantities of very dilute urine) and help remove contrast out of the kidney faster. Theoretically, they should be the first line of defense against RCN. In fact, they were used to prevent RCN based on this assumption until clinical evidence suggested that they were actually deleterious. More recently, doubts have been raised regarding the validity of those negative clinical studies.
  • furosemide-treated subjects lost 0.7 kg on average, whereas a 1.3-kg weight gain was noted in patients randomized to hydration alone, suggesting that in furosemide-treated subjects the hydration protocol has been insufficient and patients were dehydrated by excessive diuresis.
  • diuresis is widely variable and unpredictable but the fluid replacement (hydration) at a constant infusion rate is prescribed in advance.
  • fluid is typically given conservatively at 1 ml/hr per kg of body weight.
  • the actual effect of diuretic is typically not known for 4 hours (until the sufficient amount of urine is collected and measured) and it is too late and too difficult to correct any imbalance. Meanwhile, patients could be losing fluid at 500 ml/hour while receiving the replacement at only 70 ml/hour.
  • the effects of forced diuresis without balancing are illustrated in the research paper by Wakelkamp et al. “The Influence of Drug input rate on the development of tolerance to furosemide” Br J Clin. Pharmacol.
  • diuresis and natriuresis curves were generated by infusing 10 mg of I.V. furosemide over 10 min to human volunteers. From that paper it can be seen that a patient can lose 1,300 ml of urine within 8 hours following the administration of this potent diuretic. Standard unbalanced I.V. hydration at 75 ml/h will only replace 600 ml in 8 hours. As a result the patient can lose “net” 700 ml of body fluid and become dehydrated. If such patient is vulnerable to renal insult, they can suffer kidney damage.
  • the invention results from the realization that radiocontrast nephropathy in particular and patient dehydration in general can be prevented by automatically measuring the urine output of the patient and adjusting the rate of delivery of a hydration fluid to the patient to achieve, as necessary, a zero, positive, or negative net fluid balance in the patient.
  • the system typically includes a console for mounting on an IV pole.
  • the console includes an input for setting a desired fluid balance for a set therapy duration.
  • a first attachment mechanism extends from the console for hanging a urine collection chamber.
  • a second attachment mechanism extends from the console for hanging a source of hydration fluid.
  • a weighing subsystem in the console is responsive to the first attachment mechanism for weighing the patient's urine output collected in the urine collection chamber and is responsive to the second attachment mechanism for weighing the source of hydration fluid.
  • An infusion pump is integrated with the console and configured to pump hydration fluid from the source of hydration fluid into the patient.
  • a controller in the console is responsive to the set desired fluid balance, the set therapy duration, and the weighing subsystem.
  • the controller is configured to determine the patient's urine output based on the weight of the urine collection chamber, determine the amount of fluid infused into the patient, and control the infusion pump to inject hydration fluid into the patient based on the set desired fluid balance, the weight of the urine collection chamber, and the weight of the source of hydration fluid to achieve the desired fluid balance during the set therapy duration.
  • the console may include a display which displays the elapsed time of the therapy duration and the current fluid balance.
  • the system may include means for indicating, on the console, when the urine collection is empty.
  • the system may include means for indicating, on the console, when the source of hydration fluid is low on fluid.
  • the controller may be configured to determine the patient's urine output based on the rate of change of the weight of the urine collection chamber, calculate a desired infusion rate based on the determined rate of change of the weight of the urine collection chamber and the set desired fluid balance, and control the infusion pump to hydrate the patient based at least on the calculated desired infusion rate.
  • This invention also features a fluid management system including a console which includes an input for setting a desired fluid balance, a urine collection chamber, a weighing device for weighing the patient's urine output collected in the urine collection chamber, a source of hydration fluid, a pump associated with the console and configured to pump hydration fluid form the source of hydration fluid into the patient, and a controller in the console configured to: determine the patient's urine output based on the weight of the urine collection chamber, operate the pump, monitor the amount of hydration fluid injected into the patient based, and control the pump based on the set desired fluid balance, the amount of hydration fluid injected into the patient, and the determined patient urine output.
  • a console which includes an input for setting a desired fluid balance, a urine collection chamber, a weighing device for weighing the patient's urine output collected in the urine collection chamber, a source of hydration fluid, a pump associated with the console and configured to pump hydration fluid form the source of hydration fluid into the patient, and a controller in
  • This invention also features a fluid management system for a patient including a console for mounting on an IV pole.
  • the console includes an input for setting a desired fluid balance, a first attachment mechanism extends from the console for handing a urine collection chamber.
  • a weighing device in the console is responsive to the first attachment mechanism for weighing the patient's urine output collected in the urine collection chamber.
  • a controllable infusion pump is integrated with the console and configured to pump hydration fluid from a source of hydration fluid into the patient at a variable rate.
  • a controller in the console is responsive to the set desired fluid balance and the weighing device.
  • the controller is configured to determine the patient's urine output based on the rate of change of the weight of the urine collection chamber, calculate a desired infusion rate based on the determined rate of change of the weight of the urine collection chamber and the set desired fluid balance, and control the infusion pump to hydrate the patient based at least on the calculated desired infusion rate.
  • This invention further features a method of addressing contrast induced nephropathy.
  • One method includes injecting a contrast agent into a patient, imaging the patient, and including diuresis to drive any contrast agent through the patient's kidneys to reduce its toxic effects on the kidneys and prevent damage to the kidneys.
  • a desired fluid balance is set.
  • Urine expelled by the patient is collected in a urine collection bag.
  • the method typically includes weighing the urine collection bag, employing a pump to infuse the patient with fluid from a fluid source, weighing the fluid source, and automatically adjusting the pump based on the weight of the urine collection bag and the weight of the fluid source and controlling the amount of fluid infused into the patient based on the amount of urine expelled by the patient and the set desired fluid balance.
  • the method may include the step of administering a diuretic to the patient.
  • Collecting urine expelled by the patient may include catheterizing the patient.
  • Catheterizing the patient may include inserting a urinary catheter in the urinary tract of the patient.
  • Weighing the urine collection bag may include providing an indication when a urine collection bag has reached its capacity.
  • the method may further include providing an indication when the fluid source is low on fluid.
  • This invention also features a method of addressing contrast induced nephropathy for a patient who has had a contrast agent injected into the patient.
  • the method includes collecting urine expelled by the patient, determining the amount of urine expelled by the patient based on the collected urine, infusing the patient with fluid from a fluid source, determining the amount of fluid infused into the patient, and inducing diuresis to dilute the concentration of any contrast agent in the patient by automatically adjusting the amount of fluid infused into the patient from the fluid source based on the determined amount of urine expelled by the patient to balance the amount of urine expelled by the patient with the amount of fluid infused into the patient.
  • This invention also features a method of driving a toxin through a patient's kidneys, the method including collecting urine expelled by the patient.
  • the method includes determining the amount of urine expelled by the patient based on the collected urine, infusing the patient with fluid from a fluid source, determining the amount of fluid infused into the patient, and inducing diuresis by automatically adjusting the amount of fluid infused into the patient from the fluid source on the determined amount of urine expelled by the patient to balance the amount of urine expelled by the patient with the amount of fluid infused into the patient.
  • This invention also features a method of preventing kidney damage due to dehydration, the method including collecting urine expelled by the patient.
  • the method includes determining the amount of urine expelled by the patient based on the collected urine, infusing the patient with fluid from a fluid source, determining the amount of fluid infused into the patient, and maintaining the patient's hydration level by automatically adjusting the amount of fluid infused into the patient from the fluid source based on the determined amount of urine expelled by the patient to balance the amount of urine expelled by the patient with the amount of fluid infused into the patient, increasing the patient's level of hydration by infusing additional fluid based on user settings over and above fluid infused to match the patient's urine output.
  • FIG. 1 is a schematic view of an example of a patient hydration system in accordance with the subject invention
  • FIG. 2 is a schematic view of one embodiment of a patient hydration system in accordance with the subject invention wherein the weight of the urine output by a patient is measured and used as an input to control the infusion rate of an infusion pump;
  • FIG. 3 is a schematic view of another embodiment of a patient hydration system in accordance with the subject invention wherein the controller and weighing mechanism are integrated in a single control subsystem unit;
  • FIG. 4 is a flow chart depicting one example of the software associated with the controller of this invention and the method of adjusting the infusion rate based on the amount of urine output by the patient;
  • FIG. 5 is a schematic view showing another embodiment of the subject invention wherein a flow meter is used to determine the amount of urine output by the patient.
  • Patient hydration system 10 FIG. 1 according to this invention includes urine collection system 12 connected to patient P.
  • Infusion system 20 typically includes an infusion device such as infusion pump 22 (e.g., a peristaltic pump) connected to source 24 of infusion fluid 26 (e.g., saline) by tubing 28 .
  • I.V. needle 30 is inserted in a vein of patient P and is connected to infusion pump 22 via tubing 32 .
  • a control system or hydration balance means 34 detects the amount of urine output by the patient and automatically adjusts the infusion rate of infusion pump 22 to achieve, as necessary, a zero, positive, or negative net fluid balance in the patient.
  • urine collection system 12 includes catheter 14 (e.g., a Foley catheter) placed in the bladder B of patient P.
  • Tubing 16 connects catheter 14 to meter 36 .
  • Controller 38 typically programmable, is responsive to the output of meter 36 and is configured to adjust the infusion rate of infusion pump 22 .
  • meter 36 , FIG. 1 is a weight measurement device such as scale 50 , FIG. 2 .
  • urine collection chamber 52 on scale 50 is connected to catheter 14 via tubing 16 .
  • Scale 50 outputs a signal corresponding to the weight of urine or the combined weight of urine and hydration fluid (in this case to maintain net-zero hydration, the scale reading should be maintained constant) or the difference between the weight of urine and the weight of hydration fluid in collection chamber 52 to controller 38 .
  • the patient hydration system of this invention may further include diuretic administration system 60 including a source 62 of a diuretic such as furosemide administered via I.V. 64 inserted in patient P and connected to source 62 via tubing 66 .
  • tubing 66 can be connected to the patient P via hydration I.V. 30 using standard clinical techniques.
  • a urine pump such as, for example, peristaltic pump 70 can be used to urge urine from bladder B to collection chamber 52 and to automatically flush catheter 14 if it is occluded.
  • the advantage of urine collection pump 70 is that collection chamber or bag 52 can be at any height relative to the patient P.
  • chamber 24 containing the hydration fluid 26 can also be placed on scale 50 in an embodiment where differential weighing is used.
  • the controller ( 38 ) electronics and software are capable of integrating urine output (for example every 15 or 30 minutes) and changing the infusion rate setting of the infusion pump 22 following an algorithm executed by the controller.
  • Electronic controller 22 may also incorporate a more advanced feature allowing the physician to set a desired (for example positive) hydration net goal. For example, the physician may set the controller to achieve positive net gain of 400 ml in 4 hours. Controller 38 calculates the trajectory and adjusts the infusion pump flow rate setting to exceed the urine output accordingly. For example, to achieve a positive net gain of 400 ml over 4 hour, controller 38 may infuse additional 25 ml of hydration fluid every 15 minutes in addition to the volume of urine made by the patient in each 15 minute interval.
  • the programmable controller and the weighing mechanism are integrated in controller unit 34 ′′.
  • the patient (see FIG. 1 ) is placed on the hospital bed or operating table 80 .
  • the hydration I.V. 30 and the urinary collection (Foley) catheter 14 are inserted using standard methods.
  • the controller electronics and the infusion pump 22 ′ are integrated in the single enclosure of the control subsystem 34 ′′ console 82 .
  • Console 82 is mounted on I.V. pole 84 .
  • Control subsystem 34 ′′ may also include electronic air detector 86 that prevents infusion of air into the patient.
  • the air detector 86 is of ultrasonic type and can detect air in amounts exceeding approximately 50 micro liters traveling inside the infusion tubing 32 .
  • air detector 86 employs technology based on the difference of the speed of sound in liquid and in gaseous media. If an air bubble is detected, the pump 22 ′ is stopped almost instantaneously.
  • Console 82 may include one or more weight scales such as an electronic strain gage and other means to periodically detect the weight of the collected urine in chamber 52 and, if desired, the weight of the remaining hydration fluid in chamber 26 .
  • bag 52 with collected urine and the bag 24 with hydration fluid 26 are hanging off the hooks 90 and 92 connected to the balance.
  • the bags with fluids are suspended from the hooks and a system of levers translates force to a scale such as strain gage 22 ′.
  • the strain gage converts force into an electronic signal that can be read controller 34 ′′.
  • Suitable electronic devices for accurately measuring weight of a suspended bag with urine are available from Strain Measurement Devices, 130 Research Parkway, Meriden, Conn., 06450.
  • These devices include electronics and mechanical components necessary to accurately measure and monitor weight of containers with medical fluids such as one or two-liter plastic bags of collected urine.
  • medical fluids such as one or two-liter plastic bags of collected urine.
  • the overload proof single point load cell model S300 and the model S215 load cell from Strain Measurement Devices are particularly suited for scales, weighing bottles or bags in medical instrumentation applications. Options and various specifications and mounting configurations of these devices are available.
  • These low profile single point sensors are intended for limited space applications requiring accurate measurement of full-scale forces of 2, 4, and 12 pounds-force. They can be used with a rigidly mounted platform or to measure tensile or compressive forces.
  • a 10,000 ⁇ wheatstone bridge offers low power consumption for extended battery life in portable products.
  • the purpose of the weight measurement is to detect the increasing weight of the collected urine in the bag 52 and to adjust the rate of infusion or hydration based on the rate of urine flow.
  • Console 82 is also typically equipped with the user interface.
  • the interface allows the user to set (dial in) the two main parameters of therapy: the duration of hydration and the desired net fluid balance at the end.
  • the net fluid balance can be zero if no fluid gain or loss is desired.
  • Display indicators on the console show the current status of therapy: the elapsed time 100 and the net fluid gain or loss 102 .
  • the user interface may also include alarms 104 .
  • the alarms notify the user of therapy events such as an empty fluid bag or a full collection bag as detected by the weight scale.
  • the urine is collected by gravity. If urine collection unexpectedly stops for any reason, the system will reduce and, if necessary, stop the IV infusion of fluid and alarm the user.
  • the console can include the second (urine) pump (see pump 70 , FIG. 2 ) similar to infusion pump 22 . This configuration has an advantage of not depending on the bag height for drainage and the capability to automatically flush the catheter 14 , FIG. 3 if it is occluded by temporarily reversing the pump flow direction.
  • FIG. 4 illustrates an algorithm that can be used by the controller software of controller 34 ′′ to execute the desired therapy.
  • the algorithm is executed periodically based on a controller internal timer clock. It is appreciated that the algorithm can be made more complex to improve the performance and safety of the device.
  • Controller 34 ′′, FIG. 3 is programmed to determine the rate of change of the urine weight, steps 110 and 112 , FIG. 4 to calculate a desired infusion rate based on the rate of change of the urine weight, step 114 , and to adjust the infusion rate of the infusion pump 22 , FIG. 3 based on the calculated desired infusion rate, step 116 , FIG. 4 .
  • the subject invention has been described in connection with the best mode now known to the applicant.
  • the subject invention is not to be limited to these disclosed embodiments. Rather, the invention covers all of various modifications and equivalent arrangements included within the spirit and scope of the appended claims.
  • the embodiments used to illustrate the invention use the weight of the collected urine for balancing. It is understood that it is the volume of the urine that is clinically important but the weight of the urine is equivalent for any practical purpose. For the purpose of this application, 100 grams of urine are the same as 100 ml of urine. It is believed at the time of the subject invention that measuring weight is more practical than measuring volume and that the weight is often used as a clinically acceptable substitute of volume of liquids that consist mostly of water.
  • the specific gravity (specific gravity of a substance is a comparison of its density to that of water) of urine and hydration fluids is the same as water.
  • a meter which monitors the height of the column of the liquid in a vessel or by integrating the known volume of strokes of the pump over time. The exact meter used does not change the subject invention in regard to the balancing of urine output with hydration.
  • flow meter 36 ′, FIG. 5 could be used to measure the urine output of patient P and a signal corresponding to the flow rate provided to controller 38 .
  • Urine flow meter 36 ′, FIG. 5 can be one of the devices disclosed in U.S. Pat. Nos. 5,891,051; 5,176,148; 4,504,263; and 4,343,316 hereby incorporated herein by this reference.
  • the UREXACT 2000 System is an accurate electronic urine-measuring device that combines an innovative disposable collection unit with a re-usable automatic electronic meter to provide precise urine monitoring.
  • the UREXACT 2000 is based on the ultrasonic method of measuring fluid flow.

Abstract

A method includes setting a hydration goal and administering a diuretic to the patient to induce increased urine flow and collecting urine expelled by the patient. The amount of urine expelled by the patient is determined based on the collected urine. The patient is infused with fluid from a fluid source. The amount of fluid infused into the patient is determined. Diuresis is induced by automatically and continuously adjusting the amount of fluid infused into the patient from the fluid source to meet the hydration goal based on the set hydration goal, the determined amount of urine expelled by the patient and the fluid infused.

Description

    RELATED APPLICATIONS
  • This application is a divisional application of prior U.S. patent application Ser. No. 12/798,940 filed Apr. 13, 2010 and claims priority there to under 35 U.S.C. §§119, 120, 363, 365, and 37 C.F.R. §§1.55 and 1.78, which latter application is a divisional of prior U.S. patent application Ser. No. 10/936,945 filed Sep. 9, 2004, now U.S. Pat. No. 7,938,817, and both of these applications are incorporated herein by reference.
  • FIELD OF THE INVENTION
  • This invention relates to a patient hydration system and method wherein the rate of hydration fluid delivered to the patient is automatically adjusted based on the urine output of the patient to maintain, as necessary, a zero, positive, or negative net fluid balance in the patient.
  • BACKGROUND OF THE INVENTION
  • There are many medical procedures in which proper hydration of the patient is critical. For example, it has been observed that dehydration increases the risk of radiocontrast nephropathy (RCN) when radiocontrast agents are injected into a patient during coronary and peripheral vascular catheterization procedures. RCN is the third most common cause of hospital-acquired renal failure. It occurs in over 5% of patients with any baseline renal insufficiency and in 50% of patients with preexisting chronic renal insufficiency and diabetes. Radiocontrast media has a variety of physiologic effects believed to contribute to the development of RCN. One of the main contributors is renal medullary ischemia, which results from a severe, radiocontrast-induced reduction in renal/intrarenal blood flow and oxygen delivery. The medullary ischemia induces ischemia and/or death of the metabolically active areas of the medulla responsible for urine formation, called the renal tubules. Medullary ischemia is attributed to the increase of oxygen demand by the kidney struggling to remove the radiocontrast media from blood plasma and excrete it from the body at the same time as the normal process of controlling the concentration of urine. Oxygen consumption in the medulla of the kidney is directly related to the work of concentrating urine. Since the presence of radiocontrast media in the urine makes it much more difficult for the kidney to concentrate urine, the work of the medulla outstrips the available oxygen supply and leads to medullary ischemia.
  • Although the exact mechanisms of RCN remain unknown, it has been consistently observed that patients with high urine output are less vulnerable to contrast injury. It is also clear that dehydration increases the risk of RCN, likely because urine (and contrast media inside the kidney) is excessively concentrated. As a result, patients predisposed to RCN are hydrated via intravenous infusion of normal saline before, during and after the angiographic procedure. Hydration is commonly performed at a conservative rate, especially in patients with existing heart and kidney dysfunction, since over-hydration can result in pulmonary edema (fluid in the lungs), shortness of breath, the need for intubation, and even death. Thus, the patients at highest risk for RCN are those least likely to receive the only proven therapy for preventing RCN (I.V. hydration) due to the unpredictability of side effects from I.V. hydration.
  • A major limitation to the more widespread use of the already known therapeutic, or optimal, levels of I.V. hydration is the current inability to balance the amount of fluid going into the patient to the amount of fluid being removed or excreted from the patient. It is possible to have a nurse measure a patient's urine output frequently but this method is impractical as nurses are often responsible for the care of many patients. In addition, the only accurate method of measuring urine output is to place a catheter into the patient's urinary bladder. Without a catheter, the patient must excrete the urine that may have been stored in the bladder for several hours. During this time, the amount of I.V. hydration can be significantly less than the amount of urine produced by the kidneys and stored in the bladder, leading to dehydration. Since patients do not normally have such a catheter during procedures using radiocontrast media, a valid measurement of urine output is not possible.
  • There seems to be indisputable scientific evidence that RCN in patients with even mild baseline renal insufficiency can lead to long term complications and even increased risk of mortality. This scientific knowledge has not yet been extended to daily clinical practice as routine monitoring of renal function post-catheterization is not performed and limits the identification of the known short-term clinical complications.
  • At the same time, there is a great deal of awareness in clinical practice that patients with serious renal insufficiency (serum creatinine (Cr)≧2.0) often suffer serious and immediate damage from contrast. Many cardiologists go considerable length to protect these patients including slow, overnight hydration (an extra admission day), administration of marginally effective but expensive drugs, or even not performing procedures at all.
  • There are approximately 1 million inpatient and 2 million outpatient angiography and angioplasty procedures performed in the U.S. per year (based on 2001 data). Based on the largest and most representative published studies of RCN available to us (such as Mayo Clinic PCI registry of 7,586 patients) we believe that 4% of patients have serious renal insufficiency (Cr≧2.0). This results in the initial market potential of 40 to 120 thousand cases per year from interventional cardiology alone. There is also a significant potential contribution from peripheral vascular procedures, CT scans and biventricular pacemaker leads placement. As the awareness of the RCN increases, the market can be expected to increase to 10% or more of all cases involving contrast.
  • According to the prior art, hydration therapy is given intravenously (I.V.) when someone is losing necessary fluids at a rate faster than they are retaining fluids. By giving the hydration therapy with an I.V., the patient receives the necessary fluids much faster than by drinking them. Also, dehydration can be heightened by hyperemesis (vomiting), therefore the I.V. method eliminates the need to take fluids orally. An anesthetized or sedated patient may not be able to drink. Hydration is used in clinical environments such as surgery, ICU, cathlab, oncology center and many others. At this time, hydration therapy is performed using inflatable pressure bags and/or I.V. pumps. A number of I.V. pumps on the market are designed for rapid infusion of fluids (as opposed to slow I.V. drug delivery) for perioperative hydration during surgery, ICU use and even emergency use for fluid resuscitation.
  • An infusion pump is a device used in a health care facility to pump fluids into a patient in a controlled manner. The device may use a piston pump, a roller pump, or a peristaltic pump and may be powered electrically or mechanically. The device may also operate using a constant force to propel the fluid through a narrow tube, which determines the flow rate. The device may include means to detect a fault condition, such as air in, or blockage of, the infusion line and to activate an alarm.
  • An example of a device for rapid infusion of fluids is the Infusion Dynamics (Plymouth Meeting, Pa.) Power Infuser. The Power Infuser uses two alternating syringes as a pumping engine. Since it is only intended to deliver fluids (not medication), the Power Infuser has accuracy of 15%. It provides a convenient way to deliver colloid as well as crystalloid for hydration during the perioperative period among other possible clinical settings. The Power Infuser provides anesthesiologists with the ability to infuse at rates similar to that seen with pressure bags, but with more exact volume control. The maximum infusion rate is 6 L/hr. It has the flexibility of infusing fluid at 0.2, 1, 2, 4 and 6 L/hr. A bolus setting of 250 mL will deliver that volume in 2.5 min. In a large blood loss surgical case, the use of Power Infuser enables large volumes of colloid to be delivered to restore hemodynamics.
  • It is also known in the art that loop diuretics such as furosemide (frusemide) reduce sodium reabsorption and consequentially reduce oxygen consumption of the kidney. They also reduce concentration of contrast agents in the urine-collecting cavities of the kidney. They induce diuresis (e.g., patient produces large quantities of very dilute urine) and help remove contrast out of the kidney faster. Theoretically, they should be the first line of defense against RCN. In fact, they were used to prevent RCN based on this assumption until clinical evidence suggested that they were actually deleterious. More recently, doubts have been raised regarding the validity of those negative clinical studies.
  • In two clinical studies by Solomon R., Werner C, Mann D. et al. “Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents”, N Engl J Med, 1994; 331:1416-1420 and by Weinstein J. M., Heyman S., Brezis M. “Potential deleterious effect of furosemide in radiocontrast nephropathy”, Nephron 1992; 62:413-415, as compared with hydration protocol, hydration supplemented with furosemide adversely affected kidney function in high-risk patients given contrast. Weinstein et al. found that furosemide-treated subjects lost 0.7 kg on average, whereas a 1.3-kg weight gain was noted in patients randomized to hydration alone, suggesting that in furosemide-treated subjects the hydration protocol has been insufficient and patients were dehydrated by excessive diuresis.
  • The clinical problem is simple to understand: diuresis is widely variable and unpredictable but the fluid replacement (hydration) at a constant infusion rate is prescribed in advance. To avoid the risk of pulmonary edema, fluid is typically given conservatively at 1 ml/hr per kg of body weight. The actual effect of diuretic is typically not known for 4 hours (until the sufficient amount of urine is collected and measured) and it is too late and too difficult to correct any imbalance. Meanwhile, patients could be losing fluid at 500 ml/hour while receiving the replacement at only 70 ml/hour. The effects of forced diuresis without balancing are illustrated in the research paper by Wakelkamp et al. “The Influence of Drug input rate on the development of tolerance to furosemide” Br J Clin. Pharmacol. 1998; 46: 479-487. In that study, diuresis and natriuresis curves were generated by infusing 10 mg of I.V. furosemide over 10 min to human volunteers. From that paper it can be seen that a patient can lose 1,300 ml of urine within 8 hours following the administration of this potent diuretic. Standard unbalanced I.V. hydration at 75 ml/h will only replace 600 ml in 8 hours. As a result the patient can lose “net” 700 ml of body fluid and become dehydrated. If such patient is vulnerable to renal insult, they can suffer kidney damage.
  • To illustrate the concept further, the effects of diuretic therapy on RCN were recently again investigated in the PRINCE study by Stevens et al. in “A Prospective Randomized Trial of Prevention Measures in Patients at High Risk for Contrast Nephropathy, Results of the PRINCE. Study” JACC Vol. 33, No. 2, 1999 February 1999:403-11. This study demonstrated that the induction of a forced diuresis while attempting to hold the intravascular volume in a constant state with replacement of urinary losses provided a modest protective benefit against contrast-induced renal injury, and importantly, independent of baseline renal function. This is particularly true if mean urine flow rates were above 150 ml/h. Forced diuresis was induced with intravenous crystalloid, furosemide, and mannitol beginning at the start of angiography.
  • The PRINCE study showed that, in contrast to the Weinstein study, forced diuresis could be beneficial to RCN patients if the intravascular volume was held in a constant state (no dehydration). Unfortunately, there are currently no practical ways of achieving this in a clinical setting since in response to the diuretic infusion the patient's urine output changes rapidly and unpredictably. In the absence of special equipment, it requires a nurse to calculate urine output every 15-30 minutes and re-adjust the I.V. infusion rate accordingly. While this can be achieved in experimental setting, this method is not possible in current clinical practice where nursing time is very limited and one nurse is often responsible for monitoring the care of up to ten patients. In addition, frequent adjustments and measurements of this kind often result in a human error.
  • Forced hydration and forced diuresis are known art that has been practiced for a long time using a variety of drugs and equipment. There is a clear clinical need for new methods and devices that will make this therapy accurate, simple to use and safe.
  • SUMMARY OF THE INVENTION
  • It is therefore an object of this invention to provide a patient hydration system and method.
  • It is a further object of this invention to provide such a system and method which prevents kidney damage in a patient.
  • It is a further object of this invention to provide such a system and method which protects the patient undergoing a medical procedure involving a radiocontrast agent from kidney damage.
  • It is a further object of this invention to provide such a system and method which incorporates a balancing feature intended to prevent dehydration, overhydration, and to maintain a proper intravascular volume.
  • It is a further object of this invention to provide a balanced diuresis method which automatically balances fluid loss in the urine.
  • It is a further object of this invention to provide such a system and method which is accurate, easy to implement, and simple to operate.
  • It is a further object of this invention to provide such a system and method which is particularly useful in the clinical setting of forced diuresis with drugs known as I.V. loop diuretics.
  • The invention results from the realization that radiocontrast nephropathy in particular and patient dehydration in general can be prevented by automatically measuring the urine output of the patient and adjusting the rate of delivery of a hydration fluid to the patient to achieve, as necessary, a zero, positive, or negative net fluid balance in the patient.
  • This invention features, in one aspect, a fluid management system for a patient. The system typically includes a console for mounting on an IV pole. The console includes an input for setting a desired fluid balance for a set therapy duration. A first attachment mechanism extends from the console for hanging a urine collection chamber. A second attachment mechanism extends from the console for hanging a source of hydration fluid. A weighing subsystem in the console is responsive to the first attachment mechanism for weighing the patient's urine output collected in the urine collection chamber and is responsive to the second attachment mechanism for weighing the source of hydration fluid. An infusion pump is integrated with the console and configured to pump hydration fluid from the source of hydration fluid into the patient. A controller in the console is responsive to the set desired fluid balance, the set therapy duration, and the weighing subsystem. The controller is configured to determine the patient's urine output based on the weight of the urine collection chamber, determine the amount of fluid infused into the patient, and control the infusion pump to inject hydration fluid into the patient based on the set desired fluid balance, the weight of the urine collection chamber, and the weight of the source of hydration fluid to achieve the desired fluid balance during the set therapy duration.
  • In one embodiment, the console may include a display which displays the elapsed time of the therapy duration and the current fluid balance. The system may include means for indicating, on the console, when the urine collection is empty. The system may include means for indicating, on the console, when the source of hydration fluid is low on fluid. The controller may be configured to determine the patient's urine output based on the rate of change of the weight of the urine collection chamber, calculate a desired infusion rate based on the determined rate of change of the weight of the urine collection chamber and the set desired fluid balance, and control the infusion pump to hydrate the patient based at least on the calculated desired infusion rate.
  • This invention also features a fluid management system including a console which includes an input for setting a desired fluid balance, a urine collection chamber, a weighing device for weighing the patient's urine output collected in the urine collection chamber, a source of hydration fluid, a pump associated with the console and configured to pump hydration fluid form the source of hydration fluid into the patient, and a controller in the console configured to: determine the patient's urine output based on the weight of the urine collection chamber, operate the pump, monitor the amount of hydration fluid injected into the patient based, and control the pump based on the set desired fluid balance, the amount of hydration fluid injected into the patient, and the determined patient urine output.
  • This invention also features a fluid management system for a patient including a console for mounting on an IV pole. The console includes an input for setting a desired fluid balance, a first attachment mechanism extends from the console for handing a urine collection chamber. A weighing device in the console is responsive to the first attachment mechanism for weighing the patient's urine output collected in the urine collection chamber. A controllable infusion pump is integrated with the console and configured to pump hydration fluid from a source of hydration fluid into the patient at a variable rate. A controller in the console is responsive to the set desired fluid balance and the weighing device. The controller is configured to determine the patient's urine output based on the rate of change of the weight of the urine collection chamber, calculate a desired infusion rate based on the determined rate of change of the weight of the urine collection chamber and the set desired fluid balance, and control the infusion pump to hydrate the patient based at least on the calculated desired infusion rate.
  • This invention further features a method of addressing contrast induced nephropathy. One method includes injecting a contrast agent into a patient, imaging the patient, and including diuresis to drive any contrast agent through the patient's kidneys to reduce its toxic effects on the kidneys and prevent damage to the kidneys. A desired fluid balance is set. Urine expelled by the patient is collected in a urine collection bag. The method typically includes weighing the urine collection bag, employing a pump to infuse the patient with fluid from a fluid source, weighing the fluid source, and automatically adjusting the pump based on the weight of the urine collection bag and the weight of the fluid source and controlling the amount of fluid infused into the patient based on the amount of urine expelled by the patient and the set desired fluid balance.
  • In another embodiment, the method may include the step of administering a diuretic to the patient. Collecting urine expelled by the patient may include catheterizing the patient. Catheterizing the patient may include inserting a urinary catheter in the urinary tract of the patient. Weighing the urine collection bag may include providing an indication when a urine collection bag has reached its capacity. The method may further include providing an indication when the fluid source is low on fluid.
  • The subject invention, however, in other embodiments, need not achieve all these objectives and the claims hereof should not be limited to structures or methods capable of achieving these objectives.
  • This invention also features a method of addressing contrast induced nephropathy for a patient who has had a contrast agent injected into the patient. The method includes collecting urine expelled by the patient, determining the amount of urine expelled by the patient based on the collected urine, infusing the patient with fluid from a fluid source, determining the amount of fluid infused into the patient, and inducing diuresis to dilute the concentration of any contrast agent in the patient by automatically adjusting the amount of fluid infused into the patient from the fluid source based on the determined amount of urine expelled by the patient to balance the amount of urine expelled by the patient with the amount of fluid infused into the patient.
  • This invention also features a method of driving a toxin through a patient's kidneys, the method including collecting urine expelled by the patient. The method includes determining the amount of urine expelled by the patient based on the collected urine, infusing the patient with fluid from a fluid source, determining the amount of fluid infused into the patient, and inducing diuresis by automatically adjusting the amount of fluid infused into the patient from the fluid source on the determined amount of urine expelled by the patient to balance the amount of urine expelled by the patient with the amount of fluid infused into the patient.
  • This invention also features a method of preventing kidney damage due to dehydration, the method including collecting urine expelled by the patient. The method includes determining the amount of urine expelled by the patient based on the collected urine, infusing the patient with fluid from a fluid source, determining the amount of fluid infused into the patient, and maintaining the patient's hydration level by automatically adjusting the amount of fluid infused into the patient from the fluid source based on the determined amount of urine expelled by the patient to balance the amount of urine expelled by the patient with the amount of fluid infused into the patient, increasing the patient's level of hydration by infusing additional fluid based on user settings over and above fluid infused to match the patient's urine output.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • Other objects, features and advantages will occur to those skilled in the art from the following description of a preferred embodiment and the accompanying drawings, in which:
  • FIG. 1 is a schematic view of an example of a patient hydration system in accordance with the subject invention;
  • FIG. 2 is a schematic view of one embodiment of a patient hydration system in accordance with the subject invention wherein the weight of the urine output by a patient is measured and used as an input to control the infusion rate of an infusion pump;
  • FIG. 3 is a schematic view of another embodiment of a patient hydration system in accordance with the subject invention wherein the controller and weighing mechanism are integrated in a single control subsystem unit;
  • FIG. 4 is a flow chart depicting one example of the software associated with the controller of this invention and the method of adjusting the infusion rate based on the amount of urine output by the patient; and
  • FIG. 5 is a schematic view showing another embodiment of the subject invention wherein a flow meter is used to determine the amount of urine output by the patient.
  • DISCLOSURE OF THE PREFERRED EMBODIMENT
  • Aside from the preferred embodiment or embodiments disclosed below, this invention is capable of other embodiments and of being practiced or being carried out in various ways. Thus, it is to be understood that the invention is not limited in its application to the details of construction and the arrangements of components set forth in the following description or illustrated in the drawings. If only one embodiment is described herein, the claims hereof are not to be limited to that embodiment. Moreover, the claims hereof are not to be read restrictively unless there is clear and convincing evidence manifesting a certain exclusion, restriction, or disclaimer.
  • Patient hydration system 10, FIG. 1 according to this invention includes urine collection system 12 connected to patient P. Infusion system 20 typically includes an infusion device such as infusion pump 22 (e.g., a peristaltic pump) connected to source 24 of infusion fluid 26 (e.g., saline) by tubing 28. I.V. needle 30 is inserted in a vein of patient P and is connected to infusion pump 22 via tubing 32.
  • A control system or hydration balance means 34 detects the amount of urine output by the patient and automatically adjusts the infusion rate of infusion pump 22 to achieve, as necessary, a zero, positive, or negative net fluid balance in the patient. Typically, urine collection system 12 includes catheter 14 (e.g., a Foley catheter) placed in the bladder B of patient P. Tubing 16 connects catheter 14 to meter 36. Controller 38, typically programmable, is responsive to the output of meter 36 and is configured to adjust the infusion rate of infusion pump 22.
  • In one example, meter 36, FIG. 1 is a weight measurement device such as scale 50, FIG. 2. Here, urine collection chamber 52 on scale 50 is connected to catheter 14 via tubing 16. Scale 50 outputs a signal corresponding to the weight of urine or the combined weight of urine and hydration fluid (in this case to maintain net-zero hydration, the scale reading should be maintained constant) or the difference between the weight of urine and the weight of hydration fluid in collection chamber 52 to controller 38. The patient hydration system of this invention may further include diuretic administration system 60 including a source 62 of a diuretic such as furosemide administered via I.V. 64 inserted in patient P and connected to source 62 via tubing 66. In alternative embodiment, tubing 66 can be connected to the patient P via hydration I.V. 30 using standard clinical techniques. Also, if desired, a urine pump such as, for example, peristaltic pump 70 can be used to urge urine from bladder B to collection chamber 52 and to automatically flush catheter 14 if it is occluded. The advantage of urine collection pump 70 is that collection chamber or bag 52 can be at any height relative to the patient P. As shown, chamber 24 containing the hydration fluid 26 can also be placed on scale 50 in an embodiment where differential weighing is used. The controller (38) electronics and software are capable of integrating urine output (for example every 15 or 30 minutes) and changing the infusion rate setting of the infusion pump 22 following an algorithm executed by the controller.
  • Electronic controller 22 may also incorporate a more advanced feature allowing the physician to set a desired (for example positive) hydration net goal. For example, the physician may set the controller to achieve positive net gain of 400 ml in 4 hours. Controller 38 calculates the trajectory and adjusts the infusion pump flow rate setting to exceed the urine output accordingly. For example, to achieve a positive net gain of 400 ml over 4 hour, controller 38 may infuse additional 25 ml of hydration fluid every 15 minutes in addition to the volume of urine made by the patient in each 15 minute interval.
  • In the embodiment of FIG. 3, the programmable controller and the weighing mechanism are integrated in controller unit 34″. The patient (see FIG. 1) is placed on the hospital bed or operating table 80. The hydration I.V. 30 and the urinary collection (Foley) catheter 14 are inserted using standard methods. The controller electronics and the infusion pump 22′ are integrated in the single enclosure of the control subsystem 34console 82. Console 82 is mounted on I.V. pole 84.
  • Control subsystem 34″ may also include electronic air detector 86 that prevents infusion of air into the patient. The air detector 86 is of ultrasonic type and can detect air in amounts exceeding approximately 50 micro liters traveling inside the infusion tubing 32. In one example, air detector 86 employs technology based on the difference of the speed of sound in liquid and in gaseous media. If an air bubble is detected, the pump 22′ is stopped almost instantaneously.
  • Console 82 may include one or more weight scales such as an electronic strain gage and other means to periodically detect the weight of the collected urine in chamber 52 and, if desired, the weight of the remaining hydration fluid in chamber 26. In the proposed embodiment, bag 52 with collected urine and the bag 24 with hydration fluid 26 are hanging off the hooks 90 and 92 connected to the balance. The bags with fluids are suspended from the hooks and a system of levers translates force to a scale such as strain gage 22′. The strain gage converts force into an electronic signal that can be read controller 34″. Suitable electronic devices for accurately measuring weight of a suspended bag with urine are available from Strain Measurement Devices, 130 Research Parkway, Meriden, Conn., 06450. These devices include electronics and mechanical components necessary to accurately measure and monitor weight of containers with medical fluids such as one or two-liter plastic bags of collected urine. For example, the overload proof single point load cell model S300 and the model S215 load cell from Strain Measurement Devices are particularly suited for scales, weighing bottles or bags in medical instrumentation applications. Options and various specifications and mounting configurations of these devices are available. These low profile single point sensors are intended for limited space applications requiring accurate measurement of full-scale forces of 2, 4, and 12 pounds-force. They can be used with a rigidly mounted platform or to measure tensile or compressive forces. A 10,000 Ω wheatstone bridge offers low power consumption for extended battery life in portable products. Other examples of gravimetric scales used to balance medical fluids using a controller controlling the rates of fluid flow from the pumps in response to the weight information can be found in U.S. Pat. Nos. 5,910,252; 4,132,644; 4,204,957; 4,923,598; and 4,728,433 incorporated herein by this reference.
  • It is understood that there are many known ways in the art of engineering to measure weight and convert it into computer inputs. Regardless of the implementation, the purpose of the weight measurement is to detect the increasing weight of the collected urine in the bag 52 and to adjust the rate of infusion or hydration based on the rate of urine flow.
  • Console 82 is also typically equipped with the user interface. The interface allows the user to set (dial in) the two main parameters of therapy: the duration of hydration and the desired net fluid balance at the end. The net fluid balance can be zero if no fluid gain or loss is desired. Display indicators on the console show the current status of therapy: the elapsed time 100 and the net fluid gain or loss 102.
  • The user interface may also include alarms 104. The alarms notify the user of therapy events such as an empty fluid bag or a full collection bag as detected by the weight scale. In one proposed embodiment, the urine is collected by gravity. If urine collection unexpectedly stops for any reason, the system will reduce and, if necessary, stop the IV infusion of fluid and alarm the user. Alternatively, the console can include the second (urine) pump (see pump 70, FIG. 2) similar to infusion pump 22. This configuration has an advantage of not depending on the bag height for drainage and the capability to automatically flush the catheter 14, FIG. 3 if it is occluded by temporarily reversing the pump flow direction.
  • FIG. 4 illustrates an algorithm that can be used by the controller software of controller 34″ to execute the desired therapy. The algorithm is executed periodically based on a controller internal timer clock. It is appreciated that the algorithm can be made more complex to improve the performance and safety of the device. Controller 34″, FIG. 3 is programmed to determine the rate of change of the urine weight, steps 110 and 112, FIG. 4 to calculate a desired infusion rate based on the rate of change of the urine weight, step 114, and to adjust the infusion rate of the infusion pump 22, FIG. 3 based on the calculated desired infusion rate, step 116, FIG. 4.
  • So far, the subject invention has been described in connection with the best mode now known to the applicant. The subject invention, however, is not to be limited to these disclosed embodiments. Rather, the invention covers all of various modifications and equivalent arrangements included within the spirit and scope of the appended claims. Particularly, the embodiments used to illustrate the invention use the weight of the collected urine for balancing. It is understood that it is the volume of the urine that is clinically important but the weight of the urine is equivalent for any practical purpose. For the purpose of this application, 100 grams of urine are the same as 100 ml of urine. It is believed at the time of the subject invention that measuring weight is more practical than measuring volume and that the weight is often used as a clinically acceptable substitute of volume of liquids that consist mostly of water. For practical purposes, the specific gravity (specific gravity of a substance is a comparison of its density to that of water) of urine and hydration fluids is the same as water. Those skilled in the art will realize that it is possible to measure volume directly using a meter which monitors the height of the column of the liquid in a vessel or by integrating the known volume of strokes of the pump over time. The exact meter used does not change the subject invention in regard to the balancing of urine output with hydration. Also, flow meter 36′, FIG. 5 could be used to measure the urine output of patient P and a signal corresponding to the flow rate provided to controller 38. Urine flow meter 36′, FIG. 5 can be one of the devices disclosed in U.S. Pat. Nos. 5,891,051; 5,176,148; 4,504,263; and 4,343,316 hereby incorporated herein by this reference.
  • Also a medical device manufacturer, SFM Ltd., 14 Oholiav Street, Jerusalem, 94467, Israel manufactures and markets an electronic flow meter suitable for use with this invention. According to the manufacturer SFM Ltd. the UREXACT 2000 System is an accurate electronic urine-measuring device that combines an innovative disposable collection unit with a re-usable automatic electronic meter to provide precise urine monitoring. The UREXACT 2000 is based on the ultrasonic method of measuring fluid flow.
  • Thus, although specific features of the invention are shown in some drawings and not in others, this is for convenience only as each feature may be combined with any or all of the other features in accordance with the invention. The words “including”, “comprising”, “having”, and “with” as used herein are to be interpreted broadly and comprehensively and are not limited to any physical interconnection. Moreover, any embodiments disclosed in the subject application are not to be taken as the only possible embodiments. Other embodiments will occur to those skilled in the art and are within the following claims.
  • In addition, any amendment presented during the prosecution of the patent application for this patent is not a disclaimer of any claim element presented in the application as filed: those skilled in the art cannot reasonably be expected to draft a claim that would literally encompass all possible equivalents, many equivalents will be unforeseeable at the time of the amendment and are beyond a fair interpretation of what is to be surrendered (if anything), the rationale underlying the amendment may bear no more than a tangential relation to many equivalents, and/or there are many other reasons the applicant can not be expected to describe certain insubstantial substitutes for any claim element amended.

Claims (6)

1. A method comprising:
setting a hydration goal;
administering a diuretic to the patient to induce increased urine flow;
collecting urine expelled by the patient;
determining the amount of urine expelled by the patient based on the collected urine;
infusing the patient with fluid from a fluid source;
determining the amount of fluid infused into the patient;
inducing diuresis by automatically and continuously adjusting the amount of fluid infused into the patient from the fluid source to meet the hydration goal based on the set hydration goal, the determined amount of urine expelled by the patient, and the determined amount of fluid infused into the patient.
2. The method claim 1 in which collecting urine expelled by the patient includes collecting urine expelled by the patient in a urine collection bag and determining the amount of urine expelled by the patient based on the collected urine includes weighing the urine collection bag.
3. The method of claim 1 in which infusing the patient with fluid from a source includes employing a pump to infuse the patient with fluid from a fluid source.
4. The method of claim 3 in which determining the amount of fluid infused into the patient includes weighing the fluid source.
5. The method of claim 4 further including providing an indication when the fluid source is low on fluid based on the weight of the fluid source.
6. The method of 1 in which adjusting occurs every 15 minutes or less for a therapy duration.
US13/507,233 2004-09-09 2012-06-14 Goal-directed fluid therapy Abandoned US20120259308A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/507,233 US20120259308A1 (en) 2004-09-09 2012-06-14 Goal-directed fluid therapy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/936,945 US7938817B2 (en) 2004-09-09 2004-09-09 Patient hydration system and method
US12/798,940 US20100204677A1 (en) 2004-09-09 2010-04-13 Patient hydration system and method
US13/507,233 US20120259308A1 (en) 2004-09-09 2012-06-14 Goal-directed fluid therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/798,940 Division US20100204677A1 (en) 2004-09-09 2010-04-13 Patient hydration system and method

Publications (1)

Publication Number Publication Date
US20120259308A1 true US20120259308A1 (en) 2012-10-11

Family

ID=35997207

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/936,945 Active 2029-03-15 US7938817B2 (en) 2004-09-09 2004-09-09 Patient hydration system and method
US12/798,940 Abandoned US20100204677A1 (en) 2004-09-09 2010-04-13 Patient hydration system and method
US13/507,233 Abandoned US20120259308A1 (en) 2004-09-09 2012-06-14 Goal-directed fluid therapy
US13/507,234 Abandoned US20120259309A1 (en) 2004-09-09 2012-06-14 Kidney protection method

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US10/936,945 Active 2029-03-15 US7938817B2 (en) 2004-09-09 2004-09-09 Patient hydration system and method
US12/798,940 Abandoned US20100204677A1 (en) 2004-09-09 2010-04-13 Patient hydration system and method

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/507,234 Abandoned US20120259309A1 (en) 2004-09-09 2012-06-14 Kidney protection method

Country Status (6)

Country Link
US (4) US7938817B2 (en)
EP (1) EP1804889B1 (en)
JP (1) JP4782134B2 (en)
CA (1) CA2579829C (en)
ES (1) ES2527442T3 (en)
WO (1) WO2006031249A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015142617A1 (en) * 2014-03-17 2015-09-24 Plc Medical Systems, Inc. Fluid therapy method
US9526833B2 (en) 2004-09-09 2016-12-27 Plc Medical Systems, Inc. Patient hydration system with bolus function
US10045734B2 (en) 2009-01-28 2018-08-14 Plc Medical Systems, Inc. Fluid replacement device
CN109259728A (en) * 2018-09-14 2019-01-25 孟祥宝 A kind of body metabolism monitoring system recorded in real time based on amount of infusion and amount of urine
US11213621B2 (en) 2004-09-09 2022-01-04 Reprieve Cardiovascular, Inc. Fluid therapy method

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7938817B2 (en) 2004-09-09 2011-05-10 Plc Medical Systems, Inc. Patient hydration system and method
US7736354B2 (en) * 2004-09-09 2010-06-15 Plc Medical Systems, Inc. Patient hydration system with hydration state detection
US7837667B2 (en) * 2004-09-09 2010-11-23 Plc Medical Systems, Inc. Patient hydration system with abnormal condition sensing
US7758563B2 (en) 2004-09-09 2010-07-20 Plc Medical Systems, Inc. Patient hydration monitoring and maintenance system and method for use with administration of a diuretic
US7727222B2 (en) * 2004-09-09 2010-06-01 Plc Medical Systems, Inc. Patient hydration system with taper down feature
HUE038724T2 (en) 2004-11-24 2018-11-28 Bayer Healthcare Llc Devices and systems for fluid delivery
US8556846B2 (en) * 2005-07-28 2013-10-15 Gambro Uf Solutions, Inc. Blood volume controller during fluid removal
US20070088333A1 (en) * 2005-10-13 2007-04-19 G&L Consulting, Llc Method and system for infusing an osmotic solute into a patient and providing feedback control of the infusing rate
KR100810075B1 (en) 2006-06-21 2008-03-07 부산대학교 산학협력단 Monitoring system using an urine mass measuring sensor
US8057454B2 (en) 2006-08-25 2011-11-15 Kimberly-Clark Worldwide, Inc. Systems and methods for hydration sensing and monitoring
US8075513B2 (en) 2006-10-13 2011-12-13 Plc Medical Systems, Inc. Patient connection system for a balance hydration unit
JP5028067B2 (en) * 2006-10-31 2012-09-19 株式会社テクトロン Infusion supply system and infusion supply device
US8663128B2 (en) * 2006-11-14 2014-03-04 Flowsense Ltd. Diagnostic method and apparatus
WO2008085421A2 (en) 2006-12-29 2008-07-17 Medrad, Inc. Patient-based parameter generation systems for medical injection procedures
US7857803B1 (en) 2007-03-19 2010-12-28 The United States Of America As Represented By The Secretary Of The Army Burn patient resuscitation system and method
EP2170165B1 (en) 2007-07-17 2018-12-05 Bayer Healthcare LLC Systems for determination of parameters for a procedure, for estimation of cardiopulmonary function and for fluid delivery
JP4976232B2 (en) * 2007-08-22 2012-07-18 アトムメディカル株式会社 Incubator with built-in resuscitation treatment timer, incubator with resuscitation treatment timer and resuscitation treatment timer
US20090062730A1 (en) * 2007-09-01 2009-03-05 San Hoon Woo Control of body fluid condition using diuretics, based on biological parameters
US9421330B2 (en) 2008-11-03 2016-08-23 Bayer Healthcare Llc Mitigation of contrast-induced nephropathy
JP5356838B2 (en) * 2009-01-20 2013-12-04 株式会社日立製作所 Automatic urine collecting device
EP2295097A1 (en) 2009-09-09 2011-03-16 Fresenius Medical Care Deutschland GmbH Method and apparatus for evaluating values representing a mass or a concentration of a substance present within the body of a patient
GB201001069D0 (en) 2010-01-22 2010-03-10 Ucl Business Plc Method and apparatus for providing hydration fluid
CA2803169C (en) 2010-06-24 2020-09-22 Medrad, Inc. Modeling of pharmaceutical propagation and parameter generation for injection protocols
WO2012006625A2 (en) 2010-07-09 2012-01-12 Velomedix, Inc. Method and apparatus for pressure measurement
US9962516B2 (en) 2010-09-09 2018-05-08 University Of Florida Research Foundation, Incorporated Context-sensitive flow interrupter and drainage outflow optimization system
KR20120052039A (en) * 2010-11-15 2012-05-23 김성근 Apparatus and method of controlling infusion pump using urine output
EP2678002A2 (en) 2011-02-25 2014-01-01 Medtronic, Inc. Therapy for kidney disease and/or heart failure
EP3524282A1 (en) 2011-03-07 2019-08-14 Potrero Medical, Inc. Sensing foley catheter
CN107456653B (en) * 2011-07-18 2021-06-22 Empi有限公司 Electrode, electrode system and method of manufacture and iontophoretic delivery system
WO2013033675A1 (en) 2011-09-02 2013-03-07 Medtronic, Inc. Chimeric natriuretic peptide compositions and methods of preparation
EP2836113A4 (en) * 2012-04-13 2016-03-09 Capricor Therapeutics Inc Feedback-based diuretic or natriuretic molecule administration
US20130274705A1 (en) * 2012-04-13 2013-10-17 Medtronic, Inc. Feedback-based diuretic or natriuretic molecule administration
HUE056182T2 (en) 2012-05-14 2022-01-28 Bayer Healthcare Llc Systems and methods for determination of pharmaceutical fluid injection protocols based on x-ray tube voltage
WO2014049656A1 (en) * 2012-09-27 2014-04-03 テルモ株式会社 Infusion pump
ES2629038T3 (en) 2013-03-15 2017-08-07 Gambro Lundia Ab Device for extracorporeal blood treatment with tank status lights
WO2015105916A1 (en) 2014-01-07 2015-07-16 Consano, Inc. Systems, devices and methods for draining and analyzing bodily fluids
WO2015148183A1 (en) * 2014-03-24 2015-10-01 Pepsico, Inc. Hydration monitoring system
WO2015192108A1 (en) * 2014-06-12 2015-12-17 Kostov Konstantin Device and method for monitoring irregular liquid flow rates
WO2016049654A1 (en) * 2014-09-28 2016-03-31 Potrero Medical, Inc. Systems, devices and methods for sensing physiologic data and draining and analyzing bodily fluids
JP6423750B2 (en) * 2015-04-13 2018-11-14 公益財団法人ヒューマンサイエンス振興財団 Beverages or jellies to prevent the occurrence of contrast media nephropathy
US11040172B2 (en) 2015-07-20 2021-06-22 Strataca Systems Limited Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion
US11040180B2 (en) 2015-07-20 2021-06-22 Strataca Systems Limited Systems, kits and methods for inducing negative pressure to increase renal function
US11541205B2 (en) 2015-07-20 2023-01-03 Roivios Limited Coated urinary catheter or ureteral stent and method
US10918827B2 (en) 2015-07-20 2021-02-16 Strataca Systems Limited Catheter device and method for inducing negative pressure in a patient's bladder
US10926062B2 (en) 2015-07-20 2021-02-23 Strataca Systems Limited Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion
MX2018000823A (en) 2015-07-20 2018-05-15 Ureteral and bladder catheters and methods for inducing negative pressure to increase renal perfusion.
US10765834B2 (en) 2015-07-20 2020-09-08 Strataca Systems Limited Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion
US10493232B2 (en) 2015-07-20 2019-12-03 Strataca Systems Limited Ureteral catheters, bladder catheters, systems, kits and methods for inducing negative pressure to increase renal function
US11229771B2 (en) 2015-07-20 2022-01-25 Roivios Limited Percutaneous ureteral catheter
US10512713B2 (en) 2015-07-20 2019-12-24 Strataca Systems Limited Method of removing excess fluid from a patient with hemodilution
US10391275B2 (en) 2015-11-17 2019-08-27 Potrero Medical, Inc. Systems, devices and methods for draining and analyzing bodily fluids
JP2017153920A (en) * 2016-02-29 2017-09-07 直人 久保田 Suspension stand of urine sampling/urine collection bags capable of being disassembled/assembled, height adjustable and portable
CN107715234B (en) * 2017-08-29 2020-10-09 深圳市宏鑫源投资咨询有限公司 Automatic infusion alarm method and device
US20210085853A1 (en) * 2018-03-01 2021-03-25 University Of Washington Systems and methods for automated assessment and monitoring of bodily fluids
JP2021524360A (en) * 2018-05-18 2021-09-13 リプリーヴ カーディオヴァスキュラ— インコーポレイテッド Treatment methods and systems for acute decompensated heart failure
EP3753492A1 (en) 2019-06-17 2020-12-23 Diuriflux Medical SA Body fluid meter assembly, in particular for measuring diuresis
CN116328082A (en) * 2019-12-06 2023-06-27 瑞普瑞弗心血管公司 Managing fluid levels of a patient and related devices, systems, and methods
CN112972814A (en) * 2021-01-28 2021-06-18 青岛大学附属医院 Old patient rehabilitation and nursing device
CN113100770B (en) * 2021-04-12 2022-08-30 中国人民解放军陆军特色医学中心 Abdominal cavity pressure measuring equipment
CN116173346B (en) * 2023-03-01 2023-08-15 北京哈特凯尔医疗科技有限公司 Hydration treatment device

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275726A (en) * 1977-12-09 1981-06-30 Dr. Eduard Fresenius, Chemisch-Pharmazeutische Industrie Kg Apparatebau Kg Apparatus for fluid balancing under sterile conditions
US4994026A (en) * 1988-08-31 1991-02-19 W. R. Grace & Co.-Conn. Gravity flow fluid balance system
US20030114786A1 (en) * 2000-03-09 2003-06-19 Joachim Hiller Fluid counterbalancing system

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4146029A (en) 1974-04-23 1979-03-27 Ellinwood Jr Everett H Self-powered implanted programmable medication system and method
US3954010A (en) 1975-04-25 1976-05-04 Illinois Tool Works Inc. Visual and electronic battery hydrometer
DE2552304C3 (en) 1975-11-21 1980-02-21 Sartorius Gmbh, 3400 Goettingen Artificial kidney
GB1537444A (en) 1977-06-28 1978-12-29 Nycotron As Apparatus for regulating and monitoring dialysis of blood in a dialyzer
US4216462A (en) 1978-03-06 1980-08-05 General Electric Company Patient monitoring and data processing system
US4229299A (en) 1978-03-22 1980-10-21 Hoechst Aktiengesellschaft Peristaltic dialysate solution pump
US4291692A (en) * 1979-10-09 1981-09-29 University Of Utah Closed-loop infusion system, both method and apparatus, based on real time urine measurement
US4261360A (en) 1979-11-05 1981-04-14 Urethral Devices Research, Inc. Transurethral irrigation pressure controller
US4343207A (en) * 1980-02-04 1982-08-10 Crutcher Corporation Tool for spiral machining
US4343316A (en) 1980-05-16 1982-08-10 C. R. Bard, Inc. Electronic urine flow monitor
US4448207A (en) 1981-11-03 1984-05-15 Vital Metrics, Inc. Medical fluid measuring system
US4449538A (en) 1982-01-25 1984-05-22 John Corbitt Medical-electronic body fluid accounting system
US4458562A (en) * 1982-06-16 1984-07-10 Interstate Exploration, Inc. Rod wrench
US4504263A (en) * 1982-12-22 1985-03-12 Valleylab, Inc. Flow rate monitor with optical sensing chamber
US4658834A (en) 1983-03-16 1987-04-21 C.R. Bard, Inc. Medical apparatus for monitoring body liquid discharge
US4728433A (en) 1984-02-02 1988-03-01 Cd Medical, Inc. Ultrafiltration regulation by differential weighing
US4712567A (en) 1985-03-14 1987-12-15 American Hospital Supply Corporation Liquid meter assembly
DE3629732A1 (en) 1986-09-01 1988-03-03 Franz Dr Med Heinz BLADDER AND URINE PRESSURE CATHETER
US4813925A (en) 1987-04-21 1989-03-21 Medical Engineering Corporation Spiral ureteral stent
DE3720665A1 (en) 1987-06-23 1989-01-05 Schael Wilfried DEVICE FOR HAEMODIALYSIS AND HAEMOFILTRATION
US5207642A (en) 1987-08-07 1993-05-04 Baxter International Inc. Closed multi-fluid delivery system and method
DE3933025A1 (en) 1989-09-30 1991-04-11 Wiest Peter P DEVICE FOR MEASURING A PATIENT'S URINE FLOW (UROFLOW)
US5098379A (en) 1990-01-10 1992-03-24 Rochester Medical Corporation Catheter having lubricated outer sleeve and methods for making and using same
US5910252A (en) 1993-02-12 1999-06-08 Cobe Laboratories, Inc. Technique for extracorporeal treatment of blood
DE4338687C1 (en) 1993-11-12 1995-07-06 Fresenius Ag Urine meter and method for determining the density of urine
SE9400347L (en) 1994-02-03 1995-07-17 Gambro Ab Apparatus for peritoneal dialysis
US5573506A (en) * 1994-11-25 1996-11-12 Block Medical, Inc. Remotely programmable infusion system
US6749586B2 (en) 1994-11-25 2004-06-15 I-Flow Corporation Remotely programmable infusion system
US5891051A (en) 1995-06-02 1999-04-06 C.R. Bard, Inc. Electronic urine monitor
JP3619579B2 (en) 1995-08-31 2005-02-09 出光興産株式会社 Method for producing oligomeric granular material for polycarbonate solid phase polymerization
FR2748564B1 (en) 1996-05-10 1998-07-31 Corneal Ind DEVICE FOR MEASURING THE PRESSURE OF A LIQUID FLOWING IN A TUBE TOWARDS OR OUTSIDE THE HUMAN BODY
TW452586B (en) * 1996-08-09 2001-09-01 Chisso Corp Polypropylene composition, process for preparing the same and catalyst for polymerization
US7166084B2 (en) 1996-09-23 2007-01-23 Dsu Medical Corporation Blood set priming method and apparatus
US5814009A (en) 1996-10-11 1998-09-29 Cabot Technology Corporation Fluid management system and replaceable tubing assembly therefor
US6010454A (en) 1997-05-29 2000-01-04 Aquintel, Inc. Fluid and electrolyte balance monitoring system for surgical and critically ill patients
WO1999006087A1 (en) * 1997-08-01 1999-02-11 Nova-Technik Entwicklung Von Und Handel Mit Medizinischen Geräten Gmbh Installation and device for regulating fluid equilibrium in patients
US5916153A (en) 1997-10-27 1999-06-29 Rhea, Jr.; W. Gardner Multifunction catheter
US5916195A (en) 1998-02-04 1999-06-29 Argomed Ltd. Internal catheter
US6087182A (en) 1998-08-27 2000-07-11 Abbott Laboratories Reagentless analysis of biological samples
JP3601761B2 (en) 1998-11-19 2004-12-15 松下電器産業株式会社 Light receiving element and method of manufacturing the same
IL128056A (en) 1999-01-14 2005-11-20 S F M Sophisticated Water Mete Liquid metering device
US6358237B1 (en) 1999-01-19 2002-03-19 Assistive Technology Products, Inc. Methods and apparatus for delivering fluids to a patient
US6231551B1 (en) 1999-03-01 2001-05-15 Coaxia, Inc. Partial aortic occlusion devices and methods for cerebral perfusion augmentation
US6171253B1 (en) 1999-05-04 2001-01-09 Apex Medical, Inc. Flat tube pressure sensor
US6554791B1 (en) 1999-09-29 2003-04-29 Smisson-Cartledge Biomedical, Llc Rapid infusion system
US6514226B1 (en) 2000-02-10 2003-02-04 Chf Solutions, Inc. Method and apparatus for treatment of congestive heart failure by improving perfusion of the kidney
FI110305B (en) 2000-02-17 2002-12-31 Instrumentarium Oyj Device in a monitoring monitor for a patient
SE522400C2 (en) 2000-04-19 2004-02-03 Gambro Lundia Ab A method and apparatus for monitoring the flow rate of an infusion solution
DE60134191D1 (en) 2000-05-26 2008-07-10 Terumo Corp Control arrangement for a medical pump
CA2771723C (en) 2000-09-08 2016-03-29 Insulet Corporation Devices, systems and methods for patient infusion
US6616597B2 (en) 2000-12-12 2003-09-09 Datascope Investment Corp. Intra-aortic balloon catheter having a dual sensor pressure sensing system
US20020107536A1 (en) 2001-02-07 2002-08-08 Hussein Hany M. Device and method for preventing kidney failure
CA2337475A1 (en) 2001-02-22 2002-08-22 Cardio-Health-Meters Ltd. Cardio-health-meter
US6796960B2 (en) 2001-05-04 2004-09-28 Wit Ip Corporation Low thermal resistance elastic sleeves for medical device balloons
US6827702B2 (en) 2001-09-07 2004-12-07 Medtronic Minimed, Inc. Safety limits for closed-loop infusion pump control
US6740072B2 (en) 2001-09-07 2004-05-25 Medtronic Minimed, Inc. System and method for providing closed loop infusion formulation delivery
US6690280B2 (en) 2001-09-07 2004-02-10 Richard A. Citrenbaum Apparatus and process for infusion monitoring
US7135012B2 (en) 2002-02-26 2006-11-14 Harvie Mark R Automatic self cleaning bladder relief system
US8512276B2 (en) 2002-07-24 2013-08-20 Medtronic Minimed, Inc. System for providing blood glucose measurements to an infusion device
US7278983B2 (en) 2002-07-24 2007-10-09 Medtronic Minimed, Inc. Physiological monitoring device for controlling a medication infusion device
AU2003282490B2 (en) * 2002-10-03 2008-09-11 Scott Laboratories, Inc. Methods and systems for providing orthogonally redundant monitoring in a sedation and analgesia system
US20040122353A1 (en) 2002-12-19 2004-06-24 Medtronic Minimed, Inc. Relay device for transferring information between a sensor system and a fluid delivery system
JP2006518649A (en) 2003-02-24 2006-08-17 ピーエルシー システムズ インク. Methods and systems for the prevention of contrast media nephropathy
US7112177B2 (en) 2003-03-04 2006-09-26 Wolfe Tory Medical, Inc. Apparatus for monitoring intra-abdominal pressure
US7291692B2 (en) * 2003-09-25 2007-11-06 Sumitomo Chemical Company, Limited Polyarylene oxide and method of producing the same
US7029456B2 (en) * 2003-10-15 2006-04-18 Baxter International Inc. Medical fluid therapy flow balancing and synchronization system
US7758563B2 (en) 2004-09-09 2010-07-20 Plc Medical Systems, Inc. Patient hydration monitoring and maintenance system and method for use with administration of a diuretic
US20080027409A1 (en) 2004-09-09 2008-01-31 Rudko Robert I Patient hydration/fluid administration system and method
US7727222B2 (en) 2004-09-09 2010-06-01 Plc Medical Systems, Inc. Patient hydration system with taper down feature
US7938817B2 (en) 2004-09-09 2011-05-10 Plc Medical Systems, Inc. Patient hydration system and method
US7758562B2 (en) * 2004-09-09 2010-07-20 Plc Medical Systems, Inc. Patient hydration system with a redundant monitoring of hydration fluid infusion
US7837667B2 (en) 2004-09-09 2010-11-23 Plc Medical Systems, Inc. Patient hydration system with abnormal condition sensing
US7736354B2 (en) 2004-09-09 2010-06-15 Plc Medical Systems, Inc. Patient hydration system with hydration state detection
US20060064053A1 (en) 2004-09-17 2006-03-23 Bollish Stephen J Multichannel coordinated infusion system
EP1804648A4 (en) 2004-10-11 2009-07-15 Wolfe Tory Medical Inc Intra-abdominal pressure monitoring device and method
US20070088333A1 (en) 2005-10-13 2007-04-19 G&L Consulting, Llc Method and system for infusing an osmotic solute into a patient and providing feedback control of the infusing rate
US8075513B2 (en) * 2006-10-13 2011-12-13 Plc Medical Systems, Inc. Patient connection system for a balance hydration unit

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275726A (en) * 1977-12-09 1981-06-30 Dr. Eduard Fresenius, Chemisch-Pharmazeutische Industrie Kg Apparatebau Kg Apparatus for fluid balancing under sterile conditions
US4994026A (en) * 1988-08-31 1991-02-19 W. R. Grace & Co.-Conn. Gravity flow fluid balance system
US20030114786A1 (en) * 2000-03-09 2003-06-19 Joachim Hiller Fluid counterbalancing system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Mawer et al., "Value of forced diuresis in acute barbiturate poisoning", 29 June 1968, British Medical Journal, 2, 790-793. *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526833B2 (en) 2004-09-09 2016-12-27 Plc Medical Systems, Inc. Patient hydration system with bolus function
US11213621B2 (en) 2004-09-09 2022-01-04 Reprieve Cardiovascular, Inc. Fluid therapy method
US10045734B2 (en) 2009-01-28 2018-08-14 Plc Medical Systems, Inc. Fluid replacement device
US11064939B2 (en) 2009-01-28 2021-07-20 Reprieve Cardiovascular, Inc. Fluid replacement device
WO2015142617A1 (en) * 2014-03-17 2015-09-24 Plc Medical Systems, Inc. Fluid therapy method
EP3119284A4 (en) * 2014-03-17 2018-03-14 PLC Medical Systems, Inc. Fluid therapy method
US10639419B2 (en) 2014-03-17 2020-05-05 Plc Medical Systems, Inc. Fluid therapy method
EP4108171A1 (en) * 2014-03-17 2022-12-28 Reprieve Cardiovascular, Inc. Fluid therapy system
US11696985B2 (en) 2014-03-17 2023-07-11 Reprieve Cardiovascular, Inc. Fluid therapy method
CN109259728A (en) * 2018-09-14 2019-01-25 孟祥宝 A kind of body metabolism monitoring system recorded in real time based on amount of infusion and amount of urine

Also Published As

Publication number Publication date
JP4782134B2 (en) 2011-09-28
EP1804889A2 (en) 2007-07-11
US20120259309A1 (en) 2012-10-11
CA2579829A1 (en) 2006-03-23
EP1804889B1 (en) 2014-10-08
JP2008512179A (en) 2008-04-24
WO2006031249A2 (en) 2006-03-23
US20100204677A1 (en) 2010-08-12
EP1804889A4 (en) 2010-07-28
US20060052764A1 (en) 2006-03-09
ES2527442T3 (en) 2015-01-23
WO2006031249A3 (en) 2007-02-08
CA2579829C (en) 2009-07-14
US7938817B2 (en) 2011-05-10

Similar Documents

Publication Publication Date Title
US7938817B2 (en) Patient hydration system and method
US7758563B2 (en) Patient hydration monitoring and maintenance system and method for use with administration of a diuretic
US7727222B2 (en) Patient hydration system with taper down feature
US20080027409A1 (en) Patient hydration/fluid administration system and method
US8444623B2 (en) Patient hydration method
US7837667B2 (en) Patient hydration system with abnormal condition sensing
US7736354B2 (en) Patient hydration system with hydration state detection
US10639419B2 (en) Fluid therapy method
US20220152302A1 (en) Fluid therapy method
EP2010251B1 (en) Patient hydration system with abnormal condition sensing

Legal Events

Date Code Title Description
AS Assignment

Owner name: GCP IV, LLC, NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PLC MEDICAL SYSTEMS, INC.;REEL/FRAME:029623/0888

Effective date: 20130114

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION